CVRx, Inc. Common Stock (CVRX)
CVRx, Inc. is a medical device company specializing in the development of implantable neuromodulation therapies designed to treat chronic heart failure and hypertension. The company's flagship product, the Barostim Therapy, aims to restore healthy autonomic nervous system balance by stimulating the carotid baroreceptors, potentially improving symptoms and outcomes for patients with these conditions.
Company News
CVRx's Barostim device has demonstrated significant reductions in hospital visits and length of stay for heart failure patients, according to new real-world evidence presented at the THT 2025 conference and published in the Journal of Cardiac Failure.
Masimo's shares surged 8.7% after the company's newly elected Board of Directors, proposed by activist investor Quentin Koffey, won election to the two available Board seats. Investors view this as a positive development, expecting the new Board to be more responsive to shareholders.
Silk Road Medical (SILK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Unsurprisingly, Johnson & Johnson's top investments are all in the healthcare sector.